A set of clinical trials examining youth and adults with type 2 diabetes or impaired glucose tolerance has found that disease progression in adults slowed during medical treatment but resumed after treatment stopped. Youth on the same treatment had markedly poorer outcomes with continued disease progression both during and after the treatment. This research, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and based partly at Indiana University School of Medicine, was published June 9 in the journals Diabetes and Diabetes Care and presented at the American Diabetes Association Scientific Sessions in San Francisco. NIDDK is part of the National Institutes of Health.
The Restoring Insulin Secretion (RISE) Adult and Pediatric Medication Studies compared the use of different treatments among adults aged 20-65 and youth aged 10-19 with impaired glucose tolerance or early onset type 2 diabetes with the aim of preserving beta cell function – key to the body’s ability to make and release insulin.
RISE was conducted at eight study sites, including Indiana University School of Medicine. In the adult study, participants were randomly assigned to receive either long-acting insulin (glargine) for three months followed by nine months of metformin, the drug liraglutide in combination with metformin for 12 months, metformin alone for 12 months, or a placebo. Researchers, including Kieren Mather, MD, who led the study at IU School of Medicine, wanted to see whether early aggressive treatment could have a lasting effect on slowing or stopping the decline of beta cell function that occurs in people with type 2 diabetes. Participants were monitored for three additional months after treatments ended.
Results showed that adult participants had improvements in beta cell function and blood glucose control while on the treatments, with those in the liraglutide plus metformin group showing the most improvement after 12 months. However, these improvements did not persist among any of the groups after treatment ended.
“The RISE medication studies show that these treatments for type 2 diabetes do not make lasting changes to beta cells even at this early stage of worsening glucose control,” said Mather. “For adults, we saw that the treatment options were effective while people were actively on them – but people need to stay on treatment to maintain the benefits.”
In a companion paper, findings from the adult study were compared to those from the RISE Pediatric Medication Study published in 2018, which showed that beta cell function declined in the two youth treatment groups during active treatment, and worsened after treatment ended. The RISE Adult and Pediatric Medication Studies were designed together to enable direct comparison of the effect of treatment on youth and adults. The youth study compared the use of three months of insulin glargine followed by metformin for nine months to metformin alone for 12 months. Insulin glargine and metformin are the only U.S. Food and Drug Administration-approved medications for youth with type 2 diabetes.
“Though the effectiveness of these medications for adults while on treatment is reassuring, the results were worse for youth in the study both during and after treatment. This underscores the continued urgent need for new approaches to prevent and treat type 2 diabetes in youth, since the disease progresses more rapidly even when given treatment that is effective in adults,” said Tamara Hannon, MD, MS, a pediatric endocrinologist who led the Indiana University School of Medicine pediatric component of the RISE studies.
This close comparison between adults and youth receiving the same type 2 diabetes treatments supports earlier research suggesting the disease is more aggressive in youth than adults, and points to new areas of research that may help explain why.
“The RISE studies show that type 2 diabetes affects youth differently, and more aggressively, than adults, said NIDDK Director Griffin P. Rodgers, MD, MACP. “These findings demonstrate the need for continued research to identify new treatment strategies to control and treat type 2 diabetes, and underscore the need to focus on prevention efforts, especially for youth.”
The RISE Adult Medication trials (NCT01779362) were conducted at VA Puget Sound Health Care System and University of Washington, both in Seattle; Indiana University School of Medicine, Indianapolis; the University of Chicago and Jesse Brown VA Medical Center, Chicago; and the Adult Surgical study was conducted at the University of Southern California, Los Angeles (NCT01763346). The RISE Pediatric Medication Study (NCT01779375) was conducted at the Children’s Hospital Colorado/University of Colorado, Aurora; Children’s Hospital of Pittsburgh; Yale University, New Haven, Connecticut; and Indiana University, Indianapolis. The RISE Coordinating Center is at The George Washington University, Rockville, Maryland.
Learn more about RISE at www.risestudy.org.
###
IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.